Last10K.com

Acasti Pharma Inc. (ACST) SEC Filing 20-F Annual report for the fiscal year ending Saturday, March 31, 2018

SEC Filings

Acasti Pharma Inc.

CIK: 1444192 Ticker: ACST

View differences made from one year to another to evaluate Acasti Pharma Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acasti Pharma Inc..

Continue

Assess how Acasti Pharma Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 20-F Annual Report

Document And Entity Information
Note 20 - Financial Instruments
Statements Of Cash Flows (twelve Month And Month Ended 2017 Unaudited)
Statements Of Changes In Equity (twelve Month And Month Ended 2017 Unaudited)
Statements Of Changes In Equity (twelve Month And Month Ended 2017 Unaudited) (parentheticals)
Statements Of Earnings And Comprehensive Loss (twelve Month And Month Ended 2017 Unaudited)
Statements Of Financial Position (february 2017 Unaudited)
Note 1 - Reporting Entity
Note 1 - Reporting Entity (details Textual)
Note 10 - Trade And Other Payables
Note 10 - Trade And Other Payables (tables)
Note 10 - Trade And Other Payables - Components Of Trade And Other Payables (details)
Note 11 - Derivative Warrant Liabilities
Note 11 - Derivative Warrant Liabilities (details Textual)
Note 11 - Derivative Warrant Liabilities (tables)
Note 11 - Derivative Warrant Liabilities - Assumptions (details)
Note 11 - Derivative Warrant Liabilities - Reconciliation (details)
Note 12 - Unsecured Convertible Debentures
Note 12 - Unsecured Convertible Debentures (details Textual)
Note 12 - Unsecured Convertible Debentures (tables)
Note 12 - Unsecured Convertible Debentures - Liability And Equity Component Portions (details)
Note 13 - Capital And Other Components Of Equity
Note 13 - Capital And Other Components Of Equity (details Textual)
Note 13 - Capital And Other Components Of Equity (tables)
Note 13 - Capital And Other Components Of Equity - Assumptions (details)
Note 13 - Capital And Other Components Of Equity - Unsecured Convertible Debentures (details)
Note 13 - Capital And Other Components Of Equity - Warrants Outstanding (details)
Note 14 - Personnel Expenses
Note 14 - Personnel Expenses (tables)
Note 14 - Personnel Expenses - Components Of Personnel Expenses (details)
Note 15 - Financial Expenses
Note 15 - Financial Expenses (tables)
Note 15 - Financial Expenses - Components Of Finance Income (expenses) (details)
Note 16 - Share-based Payments
Note 16 - Share-based Payments (details Textual)
Note 16 - Share-based Payments (tables)
Note 16 - Share-based Payments - Option Activity (details)
Note 16 - Share-based Payments - Outstanding And Exercisable Options (details)
Note 16 - Share-based Payments - Weighted Average Assumptions (details)
Note 17 - Loss Per Share
Note 18 - Supplemental Cash Flow Disclosure
Note 18 - Supplemental Cash Flow Disclosure (tables)
Note 18 - Supplemental Cash Flow Disclosure - Changes In Non-cash Operating Items (details)
Note 18 - Supplemental Cash Flow Disclosure - Non-cash Transactions (details)
Note 19 - Income Taxes
Note 19 - Income Taxes (details Textual)
Note 19 - Income Taxes (tables)
Note 19 - Income Taxes - Deferred Tax (recovery) Expense (details)
Note 19 - Income Taxes - Reconciliation Of Effective Tax Rate (details)
Note 19 - Income Taxes - Tax Attributes And Temporary Differences Available To Reduce Future Years' Taxable Income (details)
Note 19 - Income Taxes - Unrecognized Deferred Tax Assets (details)
Note 2 - Basis Of Preparation
Note 2 - Basis Of Preparation (details Textual)
Note 20 - Financial Instruments (tables)
Note 20 - Financial Instruments - Currency Risk (details)
Note 20 - Financial Instruments - Financial Liabilities (details)
Note 20 - Financial Instruments - Interest Rate Risk (details)
Note 21 - Commitments And Contingencies
Note 21 - Commitments And Contingencies (details Textual)
Note 22 - Determination Of Fair Values
Note 22 - Determination Of Fair Values (details Textual)
Note 23 - Capital Management
Note 23 - Capital Management (details Textual)
Note 23 - Capital Management (tables)
Note 23 - Capital Management - Cash And Cash Equivalents (details)
Note 24 - Subsequent Event
Note 24 - Subsequent Event (details Textual)
Note 3 - Significant Accounting Policies
Note 3 - Significant Accounting Policies (details Textual)
Note 3 - Significant Accounting Policies (tables)
Note 3 - Significant Accounting Policies - Estimated Useful Lives And Rates (details)
Note 4 - Receivables
Note 4 - Receivables (tables)
Note 4 - Receivables - Schedule Of Receivables (details)
Note 5 - Other Assets
Note 5 - Other Assets (details Textual)
Note 6 - Related Parties
Note 6 - Related Parties (details Textual)
Note 6 - Related Parties (tables)
Note 6 - Related Parties - Administrative And Research And Development Expenses (details)
Note 6 - Related Parties - Key Management Personnel Compensation (details)
Note 7 - Government Assistance
Note 7 - Government Assistance (tables)
Note 7 - Government Assistance - Government Grants And Investment Tax Credits (details)
Note 7 - Government Assistance - Unrecognized Federal Tax Credits (details)
Note 8 - Equipment
Note 8 - Equipment (details Textual)
Note 8 - Equipment (tables)
Note 8 - Equipment - Components Of Equipment (details)
Note 9 - Intangible Assets
Note 9 - Intangible Assets (tables)
Note 9 - Intangible Assets - Components Of Intangible Assets (details)
Significant Accounting Policies (policies)
Ticker: ACST
CIK: 1444192
Form Type: 20-F Annual Report
Accession Number: 0001171843-18-004911
Submitted to the SEC: Fri Jun 29 2018 11:35:37 AM EST
Accepted by the SEC: Fri Jun 29 2018
Period: Saturday, March 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/acst/0001171843-18-004911.htm